Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

To join this study, your lung cancer must be a specific type called 'non-small cell lung cancer' (NSCLC), and it needs to be an advanced stage or have spread to other parts of your body. Importantly, your cancer must also have certain genetic changes, such as EGFR mutations or others like ALK, ROS1, or BRAF.

You must have already received some previous treatments for your lung cancer, and your cancer needs to have shown signs of growing again after these treatments. Also, doctors need to be able to measure your cancer on scans. There are also health requirements, like good overall health, and for some conditions like Hepatitis B or HIV, they must be well-managed.

People whose cancer is primarily a different type of lung cancer (called squamous cell) or has small cell elements, or who have certain other medical conditions like severe heart problems, nerve damage (neuropathy), or specific eye conditions, would not be able to take part.

Taking part in this study would involve regular visits to the hospital or clinic. You would receive either the new study drug, Sacituzumab Tirumotecan, or one of the standard chemotherapy medicines (docetaxel or pemetrexed), given through a drip into your arm.

Throughout the study, you would undergo various tests and checks, including blood tests, scans (like CT or MRI) to see how your cancer is responding, and physical examinations. These assessments help the doctors monitor your health and the effectiveness of the treatment. The total duration of your participation would depend on how your cancer responds to the treatment and your general health, and would continue as long as the treatment is benefiting you and you are tolerating it well. There will also be follow-up appointments after your treatment ends.